Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed

Ophthalmic Surgery Lasers and Imaging

Volumn 39, Issue 4, 2008, Pages 294-298

  Farah, Samer E ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE;

CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVIEW; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 51349140879     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20080701-05     Document Type: Review

References (23)

1. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AR Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5:123-132.
2. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29(6 suppl 16):10-14.
3. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870.
4. Rosenfeld PJ, Brown DM, Heler JS, et al; and MARINA Study Group. Ranibizumab for neovascutar age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
5. Brown DM, Kaiser PK, Michels M, et al; and ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
6. Avery RL, Pieramici DJ, Rabena. MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
7. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
8. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet. 2007;370:204-206.
9. Lucentis/SAILOR Dear healthcare provider letter. Genentech, Inc. web site. http://www.gene.com/gene/products/information/pdf/ healthcare-provider-letter.pdf Accessed August 20, 2007.
10. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
11. D'Amico DJ, Patel M, Adamis AP, et al; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113:992-1001.
12. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508-1521.
13. Singerman LJ, Masenson HN, Patel M, et al; and the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the V.I.S.I.O.N. trial. Br J Ophthalmol. 2008; in press.
14. Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2006;37:446-454.
15. Gonzales CR; and the VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina. 2005;25:815-827.
16. Lupovitch J, Quiram PA, Hassan TS, Williams GA. Macugen as primary therapy for AMD lesions of all angiographic subtypes. Invest Ophthalmol Vis Sci. 2006;47: E-Abstract 5217.
17. Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2007;356:748-749.
18. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;69(suppl 3):25-33.
19. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232-1239. Erratum in: J Natl Cancer Inst. 2008;100:156. J Natl Cancer Inst. 2008;100:685.
20. Cannistra SA, Matulonis U, Penson R, et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol. 2006;24(18 suppl):5006.
21. Lucentis [package insert]. San Francisco, CA: Genentech, Inc.; 2006.
22. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
23. Friberg TR; and the LEVEL Study Group. Evaluation of efficacy and safety in maintaining visual acuity with sequential treatment of neovascular AMD: the LEVEL study. Invest Ophthalmol Vis Sci. 2007;48:E-Abstract 4568.